What we still need to learn.

What remains unresolvedFor most individual alleles, the effects on transcript stability, protein abundance, catalytic activity, localization, complex assembly, and residual function are not known.

Study neededAllele-specific direction-of-effect and dosage studies using matched RNA, protein, chromatin, interaction, and rescue assays.

What remains unresolvedBroad expression does not identify which human cells become functionally limited by a particular allele, at what residual dosage, or during which developmental or physiological window.

Study neededAllele-aware, isogenic comparisons across prioritized neural, glial, immune, epithelial, muscle, bone, and other cell states, with repeated differentiation, maturation, perturbation, and rescue time courses.

What remains unresolvedThe timing, frequency, and predictors of change in communication, movement, behavior, sleep, seizures, health, and daily function remain incompletely defined.

Study neededProspective natural history with common measures repeated at defined intervals.

What remains unresolvedWhether observed differences reflect biology, ascertainment, age structure, variant distribution, or limited sample size is not yet known.

Study neededLarger age-stratified analyses with longitudinal follow-up through puberty and the transition to adulthood.

What remains unresolvedThe contributions of cortical excitability, circadian and autonomic biology, endocrine state, immune or metabolic load, treatment, and ordinary background fluctuation have not been separated.

Study neededProspective repeated-measures protocols aligning sleep, EEG, autonomic, GI, nutrition, infection, medication, hormonal, exposure, intervention, and recovery data with defined functional outcomes.

What remains unresolvedPrevalence and mechanism cannot be estimated reliably until the same systems are assessed across a sufficiently complete cohort.

Study neededA standardized multisystem core with explicit assessment status and record confirmation.

What remains unresolvedNo biomarker has yet been qualified to track disease state, predict trajectory, or measure treatment response in people with ASH1L-related disorder.

Study neededCross-model biomarker studies linking molecular and physiologic measures to longitudinal clinical outcomes.

What remains unresolvedWhich outcomes are sensitive, reliable, feasible across ages, and linked closely enough to ASH1L biology for an interventional study is not established.

Study neededOutcome-measure validation embedded in prospective natural-history research.